Gabapentin vs Pregabalin

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Epilepsy

Shared mechanism: α2δ subunit of voltage-gated calcium channels · full Epilepsy pipeline

Gabapentin

Marketed by Viatris and partners

Approved in Epilepsysmall molecule
Partial signal

NCT00007670 · Phase 3 · completed

The study used randomization, double blinding, and an active carbamazepine control in a relatively large sample of 720 participants. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Reported efficacy

VA Cooperative Study 428 (18 centers, 593 elderly patients with new-onset seizures), matching this trial's title/sponsor/design exactly. Primary endpoint (12-month trial retention): early-termination rates were gabapentin 51%, lamotrigine 44.2%, carbamazepine 64.5% (p=0.0002); gabapentin significantly outperformed carbamazepine (p=0.008) but was not shown superior to lamotrigine. Seizure control was similar across all three arms. (mixed)

Result source: NCT00007670

Pregabalin

Marketed by Viatris and partners

Approved in Epilepsysmall molecule
Weak signal

NCT01463306 · Phase 3 · completed

This was an open-label study with no randomization and no concurrent placebo or active-control arm, although it included 605 participants and some had continued from earlier studies. The primary outcomes were reported descriptively without a formal current-study comparison or statistical test, so the findings cannot establish comparative efficacy or safety.

Reported efficacy

Log-transformed (Log) 28-day Seizure Rate for All Primary Generalized Tonic-Clonic (PGTC) Seizures During 12-Week Double-Blind Treatment Phase (Day 1 up to Week 12): Log-transformed (Log) 28-day Seizure Rate for All Primary Generalized Tonic-Clonic (PGTC) Seizures During 12-Week Double-Blind Treatment Phase (Day 1 up to Week 12): Pregabalin 5 mg/kg/Day or 7 mg/kg/Day or 300 mg/Day 1.17 Seizure per 28 days (Standard Error 0.097) | Pregabalin 10 mg/kg/Day or 14 mg/kg/Day or 600 mg/Day 1.13 Seizure per 28 days (Standard Error 0.095) vs Placebo 1.14 Seizure per 28 days (Standard Error 0.098) (missed)

Result source: NCT01747915

Results for Epilepsy

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointGabapentinPregabalin
Seizure frequency, % change—Not posted · NCT00007670—Not posted · NCT00141245
50% responder rate—Not posted · NCT0000767040.6% vs 22.6%+18 vs placebo10 mg/kg/Day or 14 mg/kg/Day · wk 12 · n 97NCT01389596
3 other results
  • 53.6% vs 41.5% 14 mg/kg/Day or 12 mg/kg/Day · wk 2 · n 28 · Phase 3 · secondary NCT02072824
  • 30.5% vs 41.5% 7 mg/kg/Day or 6 mg/kg/Day · wk 2 · n 59 · Phase 3 · secondary NCT02072824
  • 29.1% vs 22.6% 2.5 mg/kg/Day or 3.5 mg/kg/Day · wk 12 · n 104 · Phase 3 · secondary NCT01389596
Seizure freedom—Not posted · NCT00007670—Not posted · NCT00141245

Seizure frequency, % change

Gabapentin
—Not posted · NCT00007670
Pregabalin
—Not posted · NCT00141245

50% responder rate

Gabapentin
—Not posted · NCT00007670
Pregabalin
40.6% vs 22.6%+18 vs placebo10 mg/kg/Day or 14 mg/kg/Day · wk 12 · n 97NCT01389596
3 other results
  • 53.6% vs 41.5% 14 mg/kg/Day or 12 mg/kg/Day · wk 2 · n 28 · Phase 3 · secondary NCT02072824
  • 30.5% vs 41.5% 7 mg/kg/Day or 6 mg/kg/Day · wk 2 · n 59 · Phase 3 · secondary NCT02072824
  • 29.1% vs 22.6% 2.5 mg/kg/Day or 3.5 mg/kg/Day · wk 12 · n 104 · Phase 3 · secondary NCT01389596

Seizure freedom

Gabapentin
—Not posted · NCT00007670
Pregabalin
—Not posted · NCT00141245
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Gabapentin: 4 of 4 rows · Pregabalin: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricGabapentinPregabalin
Dropout rate
10.1%a
NCT00603473 · Phase 3 · monotherapy
show 1 more result
32.3%
NCT00620555 · Phase 3 · registry result, not featured evidence
45.5%Direct Pregabalinb
NCT01463306 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures, Primary Generalized Tonic-Clonic Seizures · phase 3
show 33 more results
24.8%Placebo-Previous to Pregabalin-Cur
NCT01463306 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures, Primary Generalized Tonic-Clonic Seizures · phase 3
22.4%Pregabalin: Previous and Current
NCT01463306 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures, Primary Generalized Tonic-Clonic Seizures · phase 3
15.3%10 mg/kg/Day or 14 mg/kg/Day or 600 mg/Day
NCT01747915 · Phase 3 · monotherapy
20%5 mg/kg/Day or 7 mg/kg/Day or 300 mg/Day
NCT01747915 · Phase 3 · monotherapy
16.5%10 mg/kg/Day or 14 mg/kg/Day
NCT01389596 · Phase 3
9.6%2.5 mg/kg/Day or 3.5 mg/kg/Day
NCT01389596 · Phase 3
2.9%14 mg/kg/Day or 12 mg/kg/Day
NCT02072824 · Phase 3
2.8%7 mg/kg/Day or 6 mg/kg/Day
NCT02072824 · Phase 3
15.7%
NCT00351611 · Phase 4 · registry result, not featured evidence
12.2%
NCT00288639 · Phase 4 · registry result, not featured evidence
43.8%Pregabalin: 1-23 Months
NCT00448916 · Phase 3 · registry result, not featured evidence
54.5%Pregabalin: 12-16 Years
NCT00448916 · Phase 3 · registry result, not featured evidence
40%Pregabalin: 2-6 Years
NCT00448916 · Phase 3 · registry result, not featured evidence
50%Pregabalin: 7-11 Years
NCT00448916 · Phase 3 · registry result, not featured evidence
13.3%330 mg
NCT01262677 · Phase 3 · registry result, not featured evidence
9%165 mg
NCT01262677 · Phase 3 · registry result, not featured evidence
22.7%
NCT00596466 · Phase 3 · registry result, not featured evidence
0%10 mg/kg/Day
NCT00437281 · Phase 1/2 · registry result, not featured evidence
0%10 mg/kg/Day
NCT00437281 · Phase 1/2 · registry result, not featured evidence
0%10 mg/kg/Day
NCT00437281 · Phase 1/2 · registry result, not featured evidence
0%10 mg/kg/Day
NCT00437281 · Phase 1/2 · registry result, not featured evidence
0%5 mg/kg/Day
NCT00437281 · Phase 1/2 · registry result, not featured evidence
0%5 mg/kg/Day
NCT00437281 · Phase 1/2 · registry result, not featured evidence
0%5 mg/kg/Day
NCT00437281 · Phase 1/2 · registry result, not featured evidence
0%5 mg/kg/Day
NCT00437281 · Phase 1/2 · registry result, not featured evidence
0%2.5 mg/kg/Day
NCT00437281 · Phase 1/2 · registry result, not featured evidence
0%2.5 mg/kg/Day
NCT00437281 · Phase 1/2 · registry result, not featured evidence
25%2.5 mg/kg/Day
NCT00437281 · Phase 1/2 · registry result, not featured evidence
0%2.5 mg/kg/Day
NCT00437281 · Phase 1/2 · registry result, not featured evidence
33.3%15 mg/kg/Day
NCT00437281 · Phase 1/2 · registry result, not featured evidence
50%15 mg/kg/Day
NCT00437281 · Phase 1/2 · registry result, not featured evidence
0%15 mg/kg/Day
NCT00437281 · Phase 1/2 · registry result, not featured evidence
33.3%15 mg/kg/Day
NCT00437281 · Phase 1/2 · registry result, not featured evidence
Discontinued due to AEs
4.5%a
NCT00603473 · Phase 3 · monotherapy
show 1 more result
6.2%
NCT00620555 · Phase 3 · registry result, not featured evidence
27.3%Direct Pregabalinb
NCT01463306 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures, Primary Generalized Tonic-Clonic Seizures · phase 3
show 33 more results
4.3%Placebo-Previous to Pregabalin-Cur
NCT01463306 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures, Primary Generalized Tonic-Clonic Seizures · phase 3
1.6%Pregabalin: Previous and Current
NCT01463306 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures, Primary Generalized Tonic-Clonic Seizures · phase 3
6.9%10 mg/kg/Day or 14 mg/kg/Day or 600 mg/Day
NCT01747915 · Phase 3 · monotherapy
10.7%5 mg/kg/Day or 7 mg/kg/Day or 300 mg/Day
NCT01747915 · Phase 3 · monotherapy
4.1%10 mg/kg/Day or 14 mg/kg/Day
NCT01389596 · Phase 3
1%2.5 mg/kg/Day or 3.5 mg/kg/Day
NCT01389596 · Phase 3
0%14 mg/kg/Day or 12 mg/kg/Day
NCT02072824 · Phase 3
0%7 mg/kg/Day or 6 mg/kg/Day
NCT02072824 · Phase 3
12.4%
NCT00351611 · Phase 4 · registry result, not featured evidence
5.1%
NCT00288639 · Phase 4 · registry result, not featured evidence
12.5%Pregabalin: 1-23 Months
NCT00448916 · Phase 3 · registry result, not featured evidence
18.2%Pregabalin: 12-16 Years
NCT00448916 · Phase 3 · registry result, not featured evidence
13.3%Pregabalin: 2-6 Years
NCT00448916 · Phase 3 · registry result, not featured evidence
25%Pregabalin: 7-11 Years
NCT00448916 · Phase 3 · registry result, not featured evidence
7.1%330 mg
NCT01262677 · Phase 3 · registry result, not featured evidence
3%165 mg
NCT01262677 · Phase 3 · registry result, not featured evidence
5.3%
NCT00596466 · Phase 3 · registry result, not featured evidence
0%10 mg/kg/Day
NCT00437281 · Phase 1/2 · registry result, not featured evidence
0%10 mg/kg/Day
NCT00437281 · Phase 1/2 · registry result, not featured evidence
0%10 mg/kg/Day
NCT00437281 · Phase 1/2 · registry result, not featured evidence
0%10 mg/kg/Day
NCT00437281 · Phase 1/2 · registry result, not featured evidence
0%5 mg/kg/Day
NCT00437281 · Phase 1/2 · registry result, not featured evidence
0%5 mg/kg/Day
NCT00437281 · Phase 1/2 · registry result, not featured evidence
0%5 mg/kg/Day
NCT00437281 · Phase 1/2 · registry result, not featured evidence
0%5 mg/kg/Day
NCT00437281 · Phase 1/2 · registry result, not featured evidence
0%2.5 mg/kg/Day
NCT00437281 · Phase 1/2 · registry result, not featured evidence
0%2.5 mg/kg/Day
NCT00437281 · Phase 1/2 · registry result, not featured evidence
25%2.5 mg/kg/Day
NCT00437281 · Phase 1/2 · registry result, not featured evidence
0%2.5 mg/kg/Day
NCT00437281 · Phase 1/2 · registry result, not featured evidence
33.3%15 mg/kg/Day
NCT00437281 · Phase 1/2 · registry result, not featured evidence
50%15 mg/kg/Day
NCT00437281 · Phase 1/2 · registry result, not featured evidence
0%15 mg/kg/Day
NCT00437281 · Phase 1/2 · registry result, not featured evidence
33.3%15 mg/kg/Day
NCT00437281 · Phase 1/2 · registry result, not featured evidence
Serious AEs
1.1%a
NCT00603473 · Phase 3 · monotherapy
show 1 more result
3.1%
NCT00620555 · Phase 3 · registry result, not featured evidence
9.1%Direct Pregabalinb
NCT01463306 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures, Primary Generalized Tonic-Clonic Seizures · phase 3
show 33 more results
11%Placebo-Previous to Pregabalin-Cur
NCT01463306 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures, Primary Generalized Tonic-Clonic Seizures · phase 3
13.8%Pregabalin: Previous and Current
NCT01463306 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures, Primary Generalized Tonic-Clonic Seizures · phase 3
2.8%10 mg/kg/Day or 14 mg/kg/Day or 600 mg/Day
NCT01747915 · Phase 3 · monotherapy
2.7%5 mg/kg/Day or 7 mg/kg/Day or 300 mg/Day
NCT01747915 · Phase 3 · monotherapy
10.3%10 mg/kg/Day or 14 mg/kg/Day
NCT01389596 · Phase 3
4.8%2.5 mg/kg/Day or 3.5 mg/kg/Day
NCT01389596 · Phase 3
2.9%14 mg/kg/Day or 12 mg/kg/Day
NCT02072824 · Phase 3
0%7 mg/kg/Day or 6 mg/kg/Day
NCT02072824 · Phase 3
4.5%
NCT00351611 · Phase 4 · registry result, not featured evidence
—
NCT00288639 · Phase 4 · registry result, not featured evidence
50%Pregabalin: 1-23 Months
NCT00448916 · Phase 3 · registry result, not featured evidence
9.1%Pregabalin: 12-16 Years
NCT00448916 · Phase 3 · registry result, not featured evidence
20%Pregabalin: 2-6 Years
NCT00448916 · Phase 3 · registry result, not featured evidence
0%Pregabalin: 7-11 Years
NCT00448916 · Phase 3 · registry result, not featured evidence
4.4%330 mg
NCT01262677 · Phase 3 · registry result, not featured evidence
5%165 mg
NCT01262677 · Phase 3 · registry result, not featured evidence
4.1%
NCT00596466 · Phase 3 · registry result, not featured evidence
0%10 mg/kg/Day
NCT00437281 · Phase 1/2 · registry result, not featured evidence
0%10 mg/kg/Day
NCT00437281 · Phase 1/2 · registry result, not featured evidence
0%10 mg/kg/Day
NCT00437281 · Phase 1/2 · registry result, not featured evidence
0%10 mg/kg/Day
NCT00437281 · Phase 1/2 · registry result, not featured evidence
0%5 mg/kg/Day
NCT00437281 · Phase 1/2 · registry result, not featured evidence
0%5 mg/kg/Day
NCT00437281 · Phase 1/2 · registry result, not featured evidence
0%5 mg/kg/Day
NCT00437281 · Phase 1/2 · registry result, not featured evidence
0%5 mg/kg/Day
NCT00437281 · Phase 1/2 · registry result, not featured evidence
0%2.5 mg/kg/Day
NCT00437281 · Phase 1/2 · registry result, not featured evidence
0%2.5 mg/kg/Day
NCT00437281 · Phase 1/2 · registry result, not featured evidence
0%2.5 mg/kg/Day
NCT00437281 · Phase 1/2 · registry result, not featured evidence
0%2.5 mg/kg/Day
NCT00437281 · Phase 1/2 · registry result, not featured evidence
0%15 mg/kg/Day
NCT00437281 · Phase 1/2 · registry result, not featured evidence
0%15 mg/kg/Day
NCT00437281 · Phase 1/2 · registry result, not featured evidence
0%15 mg/kg/Day
NCT00437281 · Phase 1/2 · registry result, not featured evidence
33.3%15 mg/kg/Day
NCT00437281 · Phase 1/2 · registry result, not featured evidence
Most frequent reported AEs
a
somnolence 39.3%
nasopharyngitis 27%
influenza 10.1%
NCT00603473 · Phase 3 · monotherapy
show 1 more result
nasopharyngitis 43.1%
somnolence 15.4%
influenza 13.8%
NCT00620555 · Phase 3 · registry result, not featured evidence
b
headache 36.4%
abdominal pain upper 18.2%
increased appetite 18.2%
NCT01463306 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures, Primary Generalized Tonic-Clonic Seizures · phase 3
show 33 more results
upper respiratory tract infection 14.3%
somnolence 12.9%
pyrexia 10.5%
NCT01463306 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures, Primary Generalized Tonic-Clonic Seizures · phase 3
upper respiratory tract infection 15.6%
pyrexia 14.1%
weight increased 7.3%
NCT01463306 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures, Primary Generalized Tonic-Clonic Seizures · phase 3
10 mg/kg/Day or 14 mg/kg/Day or 600 mg/Day
dizziness 16.7% (placebo 6.9%)
headache 15.3% (placebo 16.7%)
somnolence 15.3% (placebo 9.7%)
NCT01747915 · Phase 3 · monotherapy
5 mg/kg/Day or 7 mg/kg/Day or 300 mg/Day
dizziness 17.3% (placebo 6.9%)
headache 9.3% (placebo 16.7%)
fatigue 6.7% (placebo 4.2%)
NCT01747915 · Phase 3 · monotherapy
10 mg/kg/Day or 14 mg/kg/Day
somnolence 25.8% (placebo 13.8%)
weight increased 13.4% (placebo 4.3%)
increased appetite 10.3% (placebo 4.3%)
NCT01389596 · Phase 3
2.5 mg/kg/Day or 3.5 mg/kg/Day
somnolence 17.3% (placebo 13.8%)
upper respiratory tract infection 9.6% (placebo 9.6%)
cough 8.7% (placebo 3.2%)
NCT01389596 · Phase 3
14 mg/kg/Day or 12 mg/kg/Day
somnolence 17.6% (placebo 5.7%)
upper respiratory tract infection 11.8% (placebo 11.4%)
nasopharyngitis 5.9% (placebo 4.3%)
NCT02072824 · Phase 3
7 mg/kg/Day or 6 mg/kg/Day
somnolence 11.3% (placebo 5.7%)
upper respiratory tract infection 7% (placebo 11.4%)
pyrexia 5.6% (placebo 5.7%)
NCT02072824 · Phase 3
dizziness 22.5% (placebo 3.1%)
somnolence 7.9% (placebo 3.1%)
fatigue 6.7% (placebo 3.1%)
NCT00351611 · Phase 4 · registry result, not featured evidence
somnolence 20.4%
dizziness 5.1%
agitation 4.1%
NCT00288639 · Phase 4 · registry result, not featured evidence
pyrexia 56.3%
constipation 31.3%
cough 25%
NCT00448916 · Phase 3 · registry result, not featured evidence
pyrexia 27.3%
excoriation 18.2%
anger 9.1%
NCT00448916 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 33.3%
ear infection 26.7%
otitis media 26.7%
NCT00448916 · Phase 3 · registry result, not featured evidence
convulsion 25%
upper respiratory tract infection 16.7%
aggression 8.3%
NCT00448916 · Phase 3 · registry result, not featured evidence
330 mg
dizziness 9.7% (placebo 1.8%)
weight increased 6.2% (placebo 0%)
fatigue 5.3% (placebo 0.9%)
NCT01262677 · Phase 3 · registry result, not featured evidence
165 mg
dizziness 11% (placebo 1.8%)
fatigue 3% (placebo 0.9%)
weight increased 1% (placebo 0%)
NCT01262677 · Phase 3 · registry result, not featured evidence
headache 5.5%
nausea 5.5%
arthralgia 4.1%
NCT00596466 · Phase 3 · registry result, not featured evidence
10 mg/kg/Day
electrocardiogram abnormal 33.3% (placebo 0%)
vomiting 33.3% (placebo 0%)
ataxia 0% (placebo 0%)
NCT00437281 · Phase 1/2 · registry result, not featured evidence
10 mg/kg/Day
dizziness 50% (placebo 0%)
chest pain 25% (placebo 0%)
fatigue 25% (placebo 0%)
NCT00437281 · Phase 1/2 · registry result, not featured evidence
10 mg/kg/Day
decreased appetite 33.3% (placebo 0%)
dizziness 33.3% (placebo 0%)
hypersomnia 33.3% (placebo 0%)
NCT00437281 · Phase 1/2 · registry result, not featured evidence
10 mg/kg/Day
lethargy 50% (placebo 0%)
muscular weakness 50% (placebo 0%)
psychomotor hyperactivity 50% (placebo 0%)
NCT00437281 · Phase 1/2 · registry result, not featured evidence
5 mg/kg/Day
somnolence 66.7% (placebo 50%)
ataxia 33.3% (placebo 0%)
balance disorder 0% (placebo 0%)
NCT00437281 · Phase 1/2 · registry result, not featured evidence
5 mg/kg/Day
irritability 33.3% (placebo 25%)
pyrexia 33.3% (placebo 0%)
sedation 33.3% (placebo 0%)
NCT00437281 · Phase 1/2 · registry result, not featured evidence
5 mg/kg/Day
dermatitis diaper 33.3% (placebo 0%)
otitis media 33.3% (placebo 0%)
pyrexia 33.3% (placebo 0%)
NCT00437281 · Phase 1/2 · registry result, not featured evidence
5 mg/kg/Day
seasonal allergy 33.3% (placebo 0%)
sinus congestion 33.3% (placebo 0%)
somnolence 33.3% (placebo 50%)
NCT00437281 · Phase 1/2 · registry result, not featured evidence
2.5 mg/kg/Day
convulsion 33.3% (placebo 0%)
ataxia 0% (placebo 0%)
balance disorder 0% (placebo 0%)
NCT00437281 · Phase 1/2 · registry result, not featured evidence
2.5 mg/kg/Day
somnolence 33.3% (placebo 50%)
ataxia 0% (placebo 0%)
balance disorder 0% (placebo 0%)
NCT00437281 · Phase 1/2 · registry result, not featured evidence
2.5 mg/kg/Day
constipation 25% (placebo 0%)
lethargy 25% (placebo 0%)
somnolence 25% (placebo 50%)
NCT00437281 · Phase 1/2 · registry result, not featured evidence
2.5 mg/kg/Day
somnolence 66.7% (placebo 50%)
ataxia 0% (placebo 0%)
balance disorder 0% (placebo 0%)
NCT00437281 · Phase 1/2 · registry result, not featured evidence
15 mg/kg/Day
somnolence 66.7% (placebo 50%)
constipation 33.3% (placebo 0%)
irritability 33.3% (placebo 25%)
NCT00437281 · Phase 1/2 · registry result, not featured evidence
15 mg/kg/Day
balance disorder 50% (placebo 0%)
dizziness 50% (placebo 0%)
nausea 50% (placebo 0%)
NCT00437281 · Phase 1/2 · registry result, not featured evidence
15 mg/kg/Day
ataxia 33.3% (placebo 0%)
constipation 33.3% (placebo 0%)
drooling 33.3% (placebo 0%)
NCT00437281 · Phase 1/2 · registry result, not featured evidence
15 mg/kg/Day
dizziness 66.7% (placebo 0%)
dry mouth 33.3% (placebo 0%)
headache 33.3% (placebo 0%)
NCT00437281 · Phase 1/2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.
  2. bPopulation comparability has not been reviewed for 31 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Gabapentin

Seizure Response -0.158 ratio @ 12wk
ratio to baseline · ratio
No placebo or comparator arm
NCT00603473 · Phase 3 · monotherapy
Seizure 50 19.8% (n=86) @ 12wk
responder rate · % of participants
No placebo or comparator arm
NCT00603473 · Phase 3 · monotherapy
Seizure Response -0.263 ratio @ 8wk
ratio to baseline · ratio
Extension (open-label)
No placebo or comparator arm
NCT00620555 · Phase 3 · registry result, not featured evidence
show 4 more results
-0.256 ratio @ 16wk
NCT00620555 · Phase 3 · registry result, not featured evidence
-0.3 ratio @ 24wk
NCT00620555 · Phase 3 · registry result, not featured evidence
-0.28 ratio @ 36wk
NCT00620555 · Phase 3 · registry result, not featured evidence
-0.327 ratio @ 52wk
NCT00620555 · Phase 3 · registry result, not featured evidence
Seizure 50 35.4% (n=65) @ 8wk
responder rate · % of participants
Extension (open-label)
No placebo or comparator arm
NCT00620555 · Phase 3 · registry result, not featured evidence
show 4 more results
40% (n=65) @ 16wk
NCT00620555 · Phase 3 · registry result, not featured evidence
39.7% (n=65) @ 24wk
NCT00620555 · Phase 3 · registry result, not featured evidence
40.7% (n=65) @ 36wk
NCT00620555 · Phase 3 · registry result, not featured evidence
46.8% (n=65) @ 52wk
NCT00620555 · Phase 3 · registry result, not featured evidence
Seizure Frequency -34.2% (n=65) @ 8wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
NCT00620555 · Phase 3 · registry result, not featured evidence
show 4 more results
-33% (n=65) @ 16wk
NCT00620555 · Phase 3 · registry result, not featured evidence
-42% (n=65) @ 24wk
NCT00620555 · Phase 3 · registry result, not featured evidence
-41.6% (n=65) @ 36wk
NCT00620555 · Phase 3 · registry result, not featured evidence
-49.2% (n=65) @ 52wk
NCT00620555 · Phase 3 · registry result, not featured evidence

Pregabalin

PGTC Seizure Rate 28-day 1.13 vs 1.14 placebo per 28 day @ 12wk10 mg/kg/Day or 14 mg/kg/Day or 600 mg/Day
absolute value · per 28 day
NCT01747915 · Phase 3 · monotherapy
show 1 more result
1.17 vs 1.14 placebo per 28 day @ 12wk5 mg/kg/Day or 7 mg/kg/Day or 300 mg/Day
NCT01747915 · Phase 3 · monotherapy
PGTC Seizure 50 38.9% (n=72) vs 41.7% (n=72) placebo @ 12wk10 mg/kg/Day or 14 mg/kg/Day or 600 mg/Day
responder rate · % of participants
NCT01747915 · Phase 3 · monotherapy
show 1 more result
41.3% (n=75) vs 41.7% (n=72) placebo @ 12wk5 mg/kg/Day or 7 mg/kg/Day or 300 mg/Day
NCT01747915 · Phase 3 · monotherapy
Partial Onset Seizure Frequency Per 28d 1.8 vs 1.93 placebo per 28 day @ 14wk330 mg
absolute value · per 28 day
NCT01262677 · Phase 3 · registry result, not featured evidence
show 3 more results
1.84 vs 1.93 placebo per 28 day @ 14wk165 mg
NCT01262677 · Phase 3 · registry result, not featured evidence
2.74 vs 2.96 placebo per 28 day @ 12wk10 mg/kg/Day or 14 mg/kg/Day
NCT01389596 · Phase 3
2.86 vs 2.96 placebo per 28 day @ 12wk2.5 mg/kg/Day or 3.5 mg/kg/Day
NCT01389596 · Phase 3
Seizure 50 53.57% (n=28) vs 41.51% (n=53) placebo @ 2wk14 mg/kg/Day or 12 mg/kg/Day
responder rate · % of participants
NCT02072824 · Phase 3
show 3 more results
40.6% (n=97) vs 22.6% (n=93) placebo @ 12wk10 mg/kg/Day or 14 mg/kg/Day
NCT01389596 · Phase 3
30.51% (n=59) vs 41.51% (n=53) placebo @ 2wk7 mg/kg/Day or 6 mg/kg/Day
NCT02072824 · Phase 3
29.1% (n=104) vs 22.6% (n=93) placebo @ 12wk2.5 mg/kg/Day or 3.5 mg/kg/Day
NCT01389596 · Phase 3
Seizure Frequency Per 1.15 vs 1.58 placebo per 24 hour @ 2wk14 mg/kg/Day or 12 mg/kg/Day
absolute value · per 24 hour
NCT02072824 · Phase 3
show 1 more result
1.69 vs 1.58 placebo per 24 hour @ 2wk7 mg/kg/Day or 6 mg/kg/Day
NCT02072824 · Phase 3
Partial Seizure Frequency -33.33% (n=92) @ 12wk
percent change · % of baseline
No placebo or comparator arm
NCT00288639 · Phase 4 · registry result, not featured evidence
show 6 more results
-29.39% (n=92) @ 21wk
NCT00288639 · Phase 4 · registry result, not featured evidence
-28.12% (n=92) @ 4wk
NCT00288639 · Phase 4 · registry result, not featured evidence
-22.5% (n=92) @ 8wk
NCT00288639 · Phase 4 · registry result, not featured evidence
-25% (n=92) @ 12wk
NCT00288639 · Phase 4 · registry result, not featured evidence
-40% (n=92) @ 16wk
NCT00288639 · Phase 4 · registry result, not featured evidence
-58.72% (n=92) @ 20wk
NCT00288639 · Phase 4 · registry result, not featured evidence
Seizure-free 19.4% (n=93) @ 12wk
event count · % of participants
No placebo or comparator arm
During 12 week Observation period (n=84)
NCT00288639 · Phase 4 · registry result, not featured evidence · converted to % from 18 participants as posted
Sleep Disturbance -3.95 score @ 21wk
absolute change · score
No placebo or comparator arm
Sleep Disturbance (n=72)
NCT00288639 · Phase 4 · registry result, not featured evidence
MOS Sleep -2.81 score @ 21wk
absolute change · score
No placebo or comparator arm
Sleep Problems Index (n=72)
NCT00288639 · Phase 4 · registry result, not featured evidence
HADS Depression -0.59 score @ 21wk
absolute change · score
No placebo or comparator arm
HADS Depression Subscale (n=76)
NCT00288639 · Phase 4 · registry result, not featured evidence
HADS Anxiety -1.68 score @ 21wk
absolute change · score
No placebo or comparator arm
HADS Anxiety Subscale (n=76)
NCT00288639 · Phase 4 · registry result, not featured evidence
Seizure Frequency NA @ 4wk
event count · count
Extension (open-label)
No placebo or comparator arm
NCT00448916 · Phase 3 · registry result, not featured evidence
show 3 more results
NA @ 4wk
NCT00448916 · Phase 3 · registry result, not featured evidence
NA @ 4wk
NCT00448916 · Phase 3 · registry result, not featured evidence
NA @ 4wk
NCT00448916 · Phase 3 · registry result, not featured evidence

+ 10 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Gabapentin's landscape · Pregabalin's landscape